Takara Holdings Inc. (TSE:2531) proposed to acquire remaining 39.09% stake in Takara Bio Inc. (TSE:4974) from group of shareholders for ¥54.1 billion on February 13, 2026. Under the terms of the acquisition, Takara Holdings Inc. will pay ¥1150 in cash per share. The tender offer will commence on February 16, 2026 and will close on April 6, 2026. Upon completion of the Tender Offer, if Takara Holdings Inc holds in aggregate of 90% or more, squeeze-out procedure will be launched. Upon completion, Takara Holdings Inc. will own 100% stake in Takara Bio Inc and shares will be delisted from the Prime Market of the TSE.
The transaction is subject to minimum tender and approval by the shareholders of Takara Bio Inc. The expected completion of the transaction is April 6, 2026.
Takara Holdings Inc. (TSE:2531) completed the acquisition of remaining 26.35% stake in Takara Bio Inc. (TSE:4974) from group of shareholders for ¥36.4 billion on April 6, 2026.
Takara Bio Inc is a Japan-based company primarily engaged in businesses related to reagents, instruments, contract services and gene therapy. The Company has one business segment. The reagents, instruments and contract services business provides biotechnology-related research reagents, laboratory instruments and contract services to universities, research institutions and corporations, offering products in the fields of molecular and cell biology based on technologies including polymerase chain reaction (PCR), next-generation sequencing, genome editing and stem cells. The Company also promotes its contract development and manufacturing organization (CDMO) business, which includes contract manufacturing of regenerative medicine products and genetic analysis services. The gene therapy business advances the development of gene therapy drugs including genetically modified T-cell therapies and next-generation chimeric antigen receptor (CAR) technologies.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
-
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
